Biotech startup Cellbox Labs, headquartered in Latvia, has secured €3.3 million in non-dilutive funding for the continued development of its product portfolio. Part of this funding comes from state support under the Important Projects of Common European Interest (IPCEI) initiative in the healthcare sector, known as “Tech4Cure”, according to a statement from the company on LinkedIn.
Cellbox Labs is known for its “organ on a chip” technology, which allows them to test medicine efficacy on specific organ cells to determine the most effective treatment option.
This funding will allow Cellbox Labs to create a new consumable product and integrate sensors that enable O₂ and pH data readings in every test without additional hardware or guesswork. The startup notes that with the advent of artificial intelligence in drug development, the industry is generating an increasing amount of data in every experiment, which makes this product especially important now.
The company is also developing a pancreas-on-a-chip model to evaluate the effects of GLP-1 generic drugs, enabling comparative analysis with existing models to support biosimilar assessment.
Meanwhile, together with ESQlabs and MPSlabs, high-precision digital twin models will be developed for Cellbox Labs’ in vitro systems to generate quantitative insights into drug efficacy.
